Exact Sciences

We’re sharing data across our expanding portfolio at #ASCO25, demonstrating our commitment to advancing cancer care through scientific excellence. Find out more: http://spr.ly/6042Najrp American Society of Clinical Oncology (ASCO)

From developing new therapies to assessing how well a medical test works, clinical trials have a clear impact on patient care. Thank you to all participants and research professionals at Exact Sciences and beyond who make clinical trials possible. Learn more about the clinical trial process with Ali Massoud: http://spr.ly/6047Ntm37 #ClinicalTrialsDay

🎉 Exciting news out of our Cologuard laboratory: we've officially processed 20 million tests! That’s 20 million results delivered. 20 million opportunities to catch cancer earlier. 20 million reasons to celebrate YOU — the patients, providers, and our amazing team here at Exact Sciences who made this milestone possible. Every test tells a story, and as of today, we’ve been part of 20 million of them. Here's to earlier detection, one test at a time — and to the next 20 million! #Cologuard #GetScreened #ColorectalCancerAwareness

📍 Munich, Germany We’re looking forward to sharing how we’re advancing cancer care while connecting with the oncology community this week at #ESMOBreast25. Learn more: http://spr.ly/6045Nbo2V ESMO - European Society for Medical Oncology

We're proud to be certified as a Great Place To Work® in the U.S. for the seventh consecutive year — and for the first time, we are internationally certified in the UK, Poland, Germany, France, Italy, Japan, and Canada! Shout out to our incredible teams across the globe for their unwavering commitment to creating positive and inclusive workplaces for all. 🔗 http://spr.ly/6043NpBYv #WeAreExact Great Place To Work US

Amy’s breast cancer diagnosis was a surprising and scary experience, but she found comfort in hearing the stories of other women who had fought the disease and survived. Now, she shares her own story to support those who are facing a diagnosis. Keep watching: http://spr.ly/6045NyeOD

We’re always looking to connect with future team members, whether you're ready for a new role now or in the future! Join the Exact Sciences Talent Community to stay engaged with our recruitment team: http://spr.ly/60472xb71 #WeAreExact

When it comes to colorectal cancer screening, choosing the right test is crucial to impacting patient health and outcomes. The Cologuard® test offers a highly sensitive, research-backed option that can help improve patient outcomes by detecting colorectal cancer early. Read more: http://spr.ly/60482LvHE

Today, we announced our first-quarter 2025 earnings results. For more information, see our press release here: http://spr.ly/60412x59t

We are delighted to announce that Leslie Trigg has joined Exact Sciences' Board of Directors. Leslie brings over 25 years of expertise within the health care and medical device industries, including senior leadership roles at Outset Medical, Inc., where she currently serves as Chair and CEO, Warburg Pincus LLC., Lutonix, Inc. (acquired by CR Bard), AccessClosure, Inc. (acquired by Cardinal Health), and FoxHollow Technologies, Inc. (acquired by ev3/Covidien). Her expertise in executive leadership, finance, commercial and corporate strategy will provide valuable insights to our organization as we continue our work to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment.